Orlistat: its current status as an anti-obesity drug (Q34635452)

3 August 2017

1 reference

title

Orlistat: its current status as an anti-obesity drug (English)

1 reference

3 August 2017

0 references

Anne Ballinger

1

1 reference

3 August 2017

Steven R Peikin

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

European Journal of Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

440

1 reference

3 August 2017

issue

2-3

1 reference

3 August 2017

page(s)

109-117

1 reference

Orlistat in the treatment of obesity

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Treatment of obesity: need to focus on high risk abdominally obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Orlistat in the long-term treatment of obesity in primary care settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

7 January 2021

Health risks of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Metabolic Control and Prevalent Cardiovascular Disease in Non-Insulin-dependent Diabetes Mellitus (NIDDM): The NIDDM Patient Outcomes Research Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Orlistat associated with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Long-term effects of modest weight loss in type II diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Treatment with orlistat reduces cardiovascular risk in obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901422-X

10.1016/S0014-2999(02)01422-X

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference